Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 17 studies | 42% ± 19% | |
lung | 10 studies | 29% ± 8% | |
eye | 8 studies | 30% ± 15% | |
peripheral blood | 5 studies | 26% ± 6% | |
heart | 5 studies | 27% ± 8% | |
liver | 5 studies | 38% ± 21% | |
intestine | 4 studies | 21% ± 6% | |
pancreas | 3 studies | 40% ± 14% | |
bone marrow | 3 studies | 26% ± 8% | |
adipose | 3 studies | 41% ± 14% | |
kidney | 3 studies | 25% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 3887.94 | 459 / 459 | 100% | 80.18 | 1118 / 1118 |
esophagus | 100% | 4481.93 | 1445 / 1445 | 100% | 67.49 | 183 / 183 |
intestine | 100% | 4361.13 | 966 / 966 | 100% | 61.95 | 527 / 527 |
lung | 100% | 3816.45 | 578 / 578 | 100% | 63.31 | 1155 / 1155 |
ovary | 100% | 3029.14 | 180 / 180 | 100% | 51.82 | 430 / 430 |
prostate | 100% | 3639.82 | 245 / 245 | 100% | 61.04 | 502 / 502 |
stomach | 100% | 3451.45 | 359 / 359 | 100% | 58.86 | 286 / 286 |
brain | 100% | 4773.46 | 2640 / 2642 | 100% | 54.39 | 705 / 705 |
thymus | 100% | 3657.49 | 653 / 653 | 100% | 53.82 | 604 / 605 |
bladder | 100% | 3962.67 | 21 / 21 | 100% | 61.78 | 503 / 504 |
uterus | 100% | 3678.04 | 170 / 170 | 100% | 63.87 | 458 / 459 |
liver | 100% | 3535.23 | 226 / 226 | 100% | 42.09 | 405 / 406 |
kidney | 100% | 3431.11 | 89 / 89 | 100% | 43.13 | 898 / 901 |
skin | 100% | 4847.15 | 1809 / 1809 | 99% | 51.11 | 468 / 472 |
adrenal gland | 100% | 3895.22 | 258 / 258 | 99% | 44.97 | 228 / 230 |
pancreas | 99% | 1940.60 | 326 / 328 | 99% | 53.15 | 176 / 178 |
blood vessel | 100% | 4043.77 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 45.84 | 29 / 29 |
muscle | 100% | 3304.16 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3216.82 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 66.12 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 48.94 | 1 / 1 |
adipose | 100% | 4008.09 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 98% | 2382.99 | 844 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 93% | 31.40 | 74 / 80 |
peripheral blood | 90% | 2788.81 | 835 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0032434 | Biological process | regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_1903265 | Biological process | positive regulation of tumor necrosis factor-mediated signaling pathway |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0060340 | Biological process | positive regulation of type I interferon-mediated signaling pathway |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0010994 | Biological process | free ubiquitin chain polymerization |
GO_0035458 | Biological process | cellular response to interferon-beta |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0010800 | Biological process | positive regulation of peptidyl-threonine phosphorylation |
GO_0032433 | Cellular component | filopodium tip |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0034450 | Molecular function | ubiquitin-ubiquitin ligase activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005524 | Molecular function | ATP binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0061631 | Molecular function | ubiquitin conjugating enzyme activity |
GO_0005515 | Molecular function | protein binding |
Gene name | UBE2K |
Protein name | Ubiquitin conjugating enzyme E2 K Ubiquitin-conjugating enzyme E2 K (EC 2.3.2.23) (E2 ubiquitin-conjugating enzyme K) (Huntingtin-interacting protein 2) (HIP-2) (Ubiquitin carrier protein) (Ubiquitin-conjugating enzyme E2-25 kDa) (Ubiquitin-conjugating enzyme E2(25K)) (Ubiquitin-conjugating enzyme E2-25K) (Ubiquitin-protein ligase) E2 ubiquitin-conjugating enzyme (EC 2.3.2.23) Alternative protein UBE2K |
Synonyms | LIG HIP2 |
Description | FUNCTION: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro, in the presence or in the absence of BRCA1-BARD1 E3 ubiquitin-protein ligase complex, catalyzes the synthesis of 'Lys-48'-linked polyubiquitin chains. Does not transfer ubiquitin directly to but elongates monoubiquitinated substrate protein. Mediates the selective degradation of short-lived and abnormal proteins, such as the endoplasmic reticulum-associated degradation (ERAD) of misfolded lumenal proteins. Ubiquitinates huntingtin. May mediate foam cell formation by the suppression of apoptosis of lipid-bearing macrophages through ubiquitination and subsequence degradation of p53/TP53. Proposed to be involved in ubiquitination and proteolytic processing of NF-kappa-B; in vitro supports ubiquitination of NFKB1. In case of infection by cytomegaloviruses may be involved in the US11-dependent degradation of MHC class I heavy chains following their export from the ER to the cytosol. In case of viral infections may be involved in the HPV E7 protein-dependent degradation of RB1. . |
Accessions | ENST00000510719.1 ENST00000503368.5 [P61086-2] D6RFX1 ENST00000510934.5 ENST00000445950.2 [P61086-3] ENST00000261427.10 [P61086-1] D6RDM7 L8E874 P61086 |